US EditionNovo Nordisk flags drug trial promise amid hunt for next weight-loss blockbuster
Cagrilintide demonstrated an average weight loss of 11.8% after 68 weeks, showing potential as a well-tolerated alternative for patients with obesity or overweight.
4 Articles
4 Articles
Why Novo Nordisk Stock Popped Today @themotleyfool #stocks $NVO
Key PointsThe pharmaceutical company had some encouraging news to report from an industry conference in Vienna.Its star weight-loss drug also has psychological benefits in relation to food, a recent study found.10 stocks we like better than Novo Nordisk › On Tuesday, there were two key news items from Novo Nordisk (NYSE: NVO) for investors to digest. The pharmaceutical company, best known for its highly popular Wegovy obesity medication, unveile…
Novo Nordisk Flags Cagrilintide Promise In Hunting for the next Obesity Medicine
The logos of the Danish drug maker Novo Nordisk, maker of the blockbuster Diabetes and weight loss treatments Ozempic and Wegovy can be seen outside Theri Building, since the company presents the annual report in Novo Nordisk in Bagvaerd, Denmark, on February 5, 2025. Mads Claus Rasmussen | AFP | Getty images Novo Nordisk On […]
Novo Nordisk, the manufacturer of Ozempic and Wegova, has published promising clinical trial results for its new obesity drug, Cagrilinitide. The Danish pharmaceutical giant is seeking a next-generation alternative to its flagship drug.
Coverage Details
Bias Distribution
- 50% of the sources lean Left, 50% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium
